» Articles » PMID: 36094655

Nanomaterials for Antigen-specific Immune Tolerance Therapy

Overview
Publisher Springer
Specialty Pharmacology
Date 2022 Sep 12
PMID 36094655
Authors
Affiliations
Soon will be listed here.
Abstract

Impairment of immune tolerance might cause autologous tissue damage or overactive immune response against non-pathogenic molecules. Although autoimmune disease and allergy have complicated pathologies, the current strategies have mainly focused on symptom amelioration or systemic immunosuppression which can lead to fatal adverse events. The induction of antigen-specific immune tolerance may provide therapeutic benefits to autoimmune disease and allergic response, while reducing nonspecific immune adverse responses. Diverse nanomaterials have been studied to induce antigen-specific immune tolerance therapy. This review will cover the immunological background of antigen-specific tolerance, clinical importance of antigen-specific immune tolerance, and nanomaterials designed for autoimmune and allergic diseases. As nanomaterials for modulating immune tolerances, lipid-based nanoparticles, polymeric nanoparticles, and biological carriers have been covered. Strategies to provide antigen-specific immune tolerance have been addressed. Finally, current challenges and perspectives of nanomaterials for antigen-specific immune tolerance therapy will be discussed.

Citing Articles

Development of protein-polymer conjugate nanoparticles for modulation of dendritic cell phenotype and antigen-specific CD4 T cell responses.

Scotland B, Cottingham A, Lasola J, Hoag S, Pearson R ACS Appl Polym Mater. 2024; 5(11):8794-8807.

PMID: 38911349 PMC: 11192461. DOI: 10.1021/acsapm.3c00548.


Vaccines for immune tolerance against autoimmune disease.

Kim A, Xie F, Abed O, Moon J Adv Drug Deliv Rev. 2023; 203:115140.

PMID: 37980949 PMC: 10757742. DOI: 10.1016/j.addr.2023.115140.

References
1.
Theofilopoulos A, Kono D, Baccala R . The multiple pathways to autoimmunity. Nat Immunol. 2017; 18(7):716-724. PMC: 5791156. DOI: 10.1038/ni.3731. View

2.
Bochner B, Rothenberg M, Boyce J, Finkelman F . Advances in mechanisms of allergy and clinical immunology in 2012. J Allergy Clin Immunol. 2013; 131(3):661-7. DOI: 10.1016/j.jaci.2012.12.676. View

3.
Vercelli D . Discovering susceptibility genes for asthma and allergy. Nat Rev Immunol. 2008; 8(3):169-82. DOI: 10.1038/nri2257. View

4.
Ronchetti S, Ayroldi E, Ricci E, Gentili M, Migliorati G, Riccardi C . A Glance at the Use of Glucocorticoids in Rare Inflammatory and Autoimmune Diseases: Still an Indispensable Pharmacological Tool?. Front Immunol. 2021; 11:613435. PMC: 7874096. DOI: 10.3389/fimmu.2020.613435. View

5.
Thomson A, Turnquist H, Raimondi G . Immunoregulatory functions of mTOR inhibition. Nat Rev Immunol. 2009; 9(5):324-37. PMC: 2847476. DOI: 10.1038/nri2546. View